Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.34 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925852 | 0.87 | DRD3 (0.37) | PTGESKCNH2HRH4 | |
| SCHEMBL2931206 | 0.86 | KCNH2 (0.35) | MAP4K1PTGESKCNH2HRH4 | |
| SCHEMBL2924534 | 0.85 | KCNH2 (0.35) | TBK1PTGESKCNH2EGLN1HRH4 | |
| SCHEMBL2931207 | 0.85 | KCNH2 (0.35) | PTGESKCNH2HRH4 | |
| SCHEMBL2923944 | 0.85 | KCNH2 (0.35) | MAP4K1TBK1PTGESKCNH2HRH4 | |
| SCHEMBL2926127 | 0.84 | KCNH2 (0.35) | TBK1PTGESKCNH2HRH4 | |
| SCHEMBL2931044 | 0.84 | PAK1 (0.39) | MAP4K1KCNH2HRH4 | |
| SCHEMBL2931516 | 0.84 | KCNH2 (0.39) | PTGESKCNH2EGLN1HRH4 | |
| SCHEMBL2927890 | 0.83 | KCNH2 (0.35) | TBK1PTGESKCNH2HRH4 | |
| SCHEMBL2931481 | 0.83 | HRH4 (0.43) | PTGESEGLN1HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | MAP4K1 401/4885TBK1 349/4885PTGES 4564/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | MAP4K1 401/4885TBK1 349/4885PTGES 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.